Regeneron Pharmaceuticals Inc (REGN) Director Sells $325,600.00 in Stock

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Director Joseph L. Goldstein sold 1,000 shares of the firm’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $325.60, for a total value of $325,600.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of Regeneron Pharmaceuticals Inc (NASDAQ REGN) traded down $18.10 during trading hours on Tuesday, hitting $324.57. The stock had a trading volume of 1,403,615 shares, compared to its average volume of 1,066,957. Regeneron Pharmaceuticals Inc has a 1 year low of $314.99 and a 1 year high of $543.55. The stock has a market capitalization of $34,890.00, a PE ratio of 31.45, a price-to-earnings-growth ratio of 1.27 and a beta of 1.47. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.18 and a current ratio of 3.82.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 earnings per share for the quarter, beating the consensus estimate of $4.18 by $1.05. The company had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.50 billion. Regeneron Pharmaceuticals had a return on equity of 28.48% and a net margin of 20.41%. Regeneron Pharmaceuticals’s quarterly revenue was up 28.9% on a year-over-year basis. During the same period last year, the business earned $3.04 earnings per share. research analysts expect that Regeneron Pharmaceuticals Inc will post 14.13 EPS for the current fiscal year.

A number of equities research analysts recently weighed in on the company. Barclays downgraded Regeneron Pharmaceuticals from an “equal weight” rating to an “underweight” rating and dropped their price objective for the company from $450.00 to $395.00 in a research report on Friday, October 20th. Canaccord Genuity reissued a “buy” rating on shares of Regeneron Pharmaceuticals in a report on Monday, October 16th. Jefferies Group reissued a “hold” rating and issued a $421.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, February 2nd. Morgan Stanley raised their price target on Regeneron Pharmaceuticals from $401.00 to $415.00 and gave the stock an “equal weight” rating in a report on Friday. Finally, JPMorgan Chase & Co. reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, November 28th. Four research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and eleven have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $463.19.

A number of hedge funds have recently made changes to their positions in the stock. Harding Loevner LP raised its position in Regeneron Pharmaceuticals by 589.2% during the third quarter. Harding Loevner LP now owns 3,663,548 shares of the biopharmaceutical company’s stock valued at $286,619,000 after acquiring an additional 3,131,966 shares in the last quarter. Polen Capital Management LLC raised its position in Regeneron Pharmaceuticals by 1.2% during the fourth quarter. Polen Capital Management LLC now owns 1,389,545 shares of the biopharmaceutical company’s stock valued at $522,413,000 after acquiring an additional 15,931 shares in the last quarter. American Century Companies Inc. raised its position in Regeneron Pharmaceuticals by 2.3% during the third quarter. American Century Companies Inc. now owns 917,554 shares of the biopharmaceutical company’s stock valued at $410,257,000 after acquiring an additional 20,218 shares in the last quarter. Geode Capital Management LLC raised its position in Regeneron Pharmaceuticals by 3.6% during the fourth quarter. Geode Capital Management LLC now owns 880,481 shares of the biopharmaceutical company’s stock valued at $330,385,000 after acquiring an additional 30,581 shares in the last quarter. Finally, Orbimed Advisors LLC raised its position in Regeneron Pharmaceuticals by 22.7% during the third quarter. Orbimed Advisors LLC now owns 572,770 shares of the biopharmaceutical company’s stock valued at $256,097,000 after acquiring an additional 106,000 shares in the last quarter. Institutional investors own 65.89% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Regeneron Pharmaceuticals Inc (REGN) Director Sells $325,600.00 in Stock” was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.americanbankingnews.com/2018/02/13/regeneron-pharmaceuticals-inc-regn-director-sells-325600-00-in-stock.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Insider Buying and Selling by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply